We are live on ! Find out more
XERS icon

Xeris Biopharma Holdings
XERS

92 hedge funds and large institutions have $80.4M invested in Xeris Biopharma Holdings in 2023 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 27 increasing their positions, 24 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

980% more call options, than puts

Call options by funds: $659K | Put options by funds: $61K

13% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 24

12% more capital invested

Capital invested by funds: $71.6M → $80.4M (+$8.75M)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

3.58% less ownership

Funds ownership: 39.61% → 36.03% (-3.6%)

5% less funds holding

Funds holding: 97 → 92 (-5)

36% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 14

Holders
92
Holders Change
-5
Holders Change %
-5.15%
% of All Funds
1.47%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
9
Increased
27
Reduced
24
Closed
14
Calls
$659K
Puts
$61K
Net Calls
+$598K
Net Calls Change
-$1.22M

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$841K
2
RCMNY
Rubric Capital Management (New York)
New York
+$534K
3
GCP
GSA Capital Partners
United Kingdom
+$396K
4
DAM
Deltec Asset Management
New York
+$317K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$304K

Top Sellers

Rank Fund Capital Flow
1
NMC
NEA Management Company
Maryland
-$4.32M
2
SCM
Stonepine Capital Management
Oregon
-$3.2M
3
Millennium Management
Millennium Management
New York
-$923K
4
BlackRock
BlackRock
New York
-$204K
5
BCM
Bridgeway Capital Management
Texas
-$125K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Stonepine Capital Management
Oregon
$14.1M -$3.2M -2,554,984 -23%
BlackRock
2
BlackRock
New York
$13.7M -$204K -163,033 -2%
Vanguard Group
3
Vanguard Group
Pennsylvania
$11.2M +$304K +243,128 +4%
CC
4
Caxton Corporation
New Jersey
$9.84M – – –
Geode Capital Management
5
Geode Capital Management
Massachusetts
$4.13M +$123K +97,994 +4%
State Street
6
State Street
Massachusetts
$3.72M +$173K +138,341 +6%
Invesco
7
Invesco
Georgia
$3.43M +$2.85K +2,276 +0.1%
Northern Trust
8
Northern Trust
Illinois
$1.81M +$16.5K +13,205 +1%
RG
9
Redmile Group
California
$1.71M – – –
Tudor Investment Corp
10
Tudor Investment Corp
Connecticut
$1.56M – – –
JP Morgan Chase
11
JP Morgan Chase
New York
$1.25M +$841K +671,873 +712%
DAM
12
Deltec Asset Management
New York
$1.01M +$317K +253,146 +69%
Renaissance Technologies
13
Renaissance Technologies
New York
$984K +$132K +105,400 +21%
Ameriprise
14
Ameriprise
Minnesota
$928K -$1.03K -820 -0.1%
RCMNY
15
Rubric Capital Management (New York)
New York
$695K +$534K +426,267 New
N
16
Nuveen
North Carolina
$687K -$6.77K -5,405 -1%
Bank of New York Mellon
17
Bank of New York Mellon
New York
$670K +$486 +388 +0.1%
AGM
18
Alpine Global Management
New York
$652K – – –
Charles Schwab
19
Charles Schwab
California
$611K +$33.5K +26,754 +8%
GCP
20
GSA Capital Partners
United Kingdom
$515K +$396K +316,025 New
Lazard Asset Management
21
Lazard Asset Management
New York
$471K -$71.3K -56,932 -16%
IWM
22
IHT Wealth Management
Illinois
$459K -$19.3K -15,425 -5%
BCM
23
Bridgeway Capital Management
Texas
$431K -$125K -100,000 -27%
Brown Advisory
24
Brown Advisory
Maryland
$385K – – –
XT
25
XTX Topco
Cayman Islands
$380K +$55.7K +44,474 +24%
1
2 3 4 5

XERS Hedge Fund Activity: Q1 2023 in Review

92 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q1 2023, worth a combined $80.4M — up 12% from $71.6M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of XERS and 9 opened new positions — a net loss of 5 holders — while 24 trimmed existing stakes and 27 added.

The largest buyer was JP Morgan Chase, adding an estimated $841K. The largest seller was NEA Management Company, exiting entirely with an estimated $4.32M sold.

  • 92 institutional investors held Xeris Biopharma Holdings (XERS) as of Q1 2023, down from 97 in Q4 2022.
  • Funds reported $80.4M of Xeris Biopharma Holdings stock for Q1 2023, up 12% quarter-over-quarter.
  • 9 funds opened new Xeris Biopharma Holdings positions in Q1 2023 and 14 closed out, a net change of -5 holders.
  • The largest Xeris Biopharma Holdings buyer in Q1 2023 was JP Morgan Chase, an estimated $841K added.
  • The largest Xeris Biopharma Holdings seller in Q1 2023 was NEA Management Company, an estimated $4.32M sold.

Based on aggregated 13F filings for Q1 2023.